Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
The Motley Fool August 8, 2008 Brian Lawler	Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest.
The Motley Fool October 31, 2006 Brian Lawler	Novo Nordisk Still Knows Sales There's more competition in diabetes care now, but the Danish pharmaceutical is thriving. Investors, take note.
The Motley Fool April 30, 2008 Brian Lawler	A Dominating Danish Drugmaker Novo Nordisk turns in solid first-quarter financial numbers.
The Motley Fool October 31, 2008 Brian Orelli	Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales..
The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
The Motley Fool September 30, 2008 Brian Lawler	Novo Nordisk Takes On All Comers Its diabetes franchise is about to get bigger.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool June 24, 2008 Brian Orelli	A Diabetes Drug Delivery Deal Several pharmaceutical companies compete to deliver a diabetes medication that can be taken orally or once-weekly.
The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool June 9, 2008 Brian Lawler	Novo Nordisk's Daring Success Novo Nordisk's potential blockbuster compound excels in late-stage head-to-head testing. Investors, take note.
The Motley Fool January 28, 2005 Stephen D. Simpson	An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk.
The Motley Fool August 12, 2005 Stephen D. Simpson	Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market.
Chemistry World September 24, 2012 Andrew Turley	$100m of diabetes R&D in China Danish drug maker Novo Nordisk has announced plans to invest $100 million in its R&D site in Beijing, China. The move will create 130 -- 200 new research jobs.
The Motley Fool April 28, 2005 Stephen D. Simpson	Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical.
The Motley Fool June 13, 2008 Brian Lawler	Novo Nordisk Bleeds a Little The pharmaceutical's hot streak ends as a vital study fizzles out.
Chemistry World June 16, 2014 Phillip Broadwith	Novo Nordisk to create 6000 jobs by 2022 Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D.
The Motley Fool November 21, 2007 Brian Orelli	Phase 2 Data to Sink Your Teeth Into Novo Nordisk releases encouraging phase 2 clinical data about its weight-loss/diabetes drug, liraglutide. Investors, take note.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
Chemistry World November 9, 2010 Andrew Turley	Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
Chemistry World September 3, 2014 Phillip Broadwith	Novo Nordisk quits inflammation R&D and cuts jobs Novo Nordisk is terminating its inflammatory disease R&D programs after the company's leading rheumatoid arthritis drug candidate failed in clinical trials.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
BusinessWeek April 30, 2010 Drew Armstrong	The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
The Motley Fool October 22, 2008 Brian Orelli	Why Amylin Skipped Some Byetta Numbers Usually the company presents the individual sales numbers for its two diabetes drugs from the year-ago quarter for investors to compare. But this time they were conspicuously absent.
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool February 28, 2007 Brian Lawler	No Dice for Novo Novo Nordisk reports a failed clinical trial for one of its top drugs. Shares were down more than 5% on the news.
The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
The Motley Fool July 27, 2007 Rich Duprey	Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note.
The Motley Fool July 22, 2009 Brian Orelli	The Blockbuster Around the Corner Amylin Pharmaceuticals' Byetta sales are improving, but is it enough?
The Motley Fool October 31, 2007 Brian Lawler	Nastech Still Breathing Coming phase 2 results on four different compounds will help investors assess how well Nastech's nasally-administered drugs might sell. Investors, take note.
The Motley Fool February 29, 2008 Brian Lawler	Nektar Squeezing Along Nektar Therapeutics finishes a topsy-turvy 2007, and gives some good guidance for upcoming year.
Managed Care June 2007	Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006.
The Motley Fool October 19, 2007 Brian Lawler	The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
The Motley Fool June 18, 2010 Brian Orelli	Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed.
The Motley Fool December 12, 2008 Brian Orelli	Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
The Motley Fool June 11, 2008 Brian Orelli	Amylin's Down and Up on Diabetes Investors may be over-reacting to news both good and bad from Amylin Pharmaceuticals.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Diabetes: Agonists versus Inhibitors Diabetes is pharma's second-largest global market, worth close to $25 billion and growing by double digits annually, even in the developed world.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool May 29, 2008 Brian Lawler	Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing.